Compare Manchester United PLC (MANU) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs Regeneron Pharmaceuticals Inc — how do they compare? Manchester United PLC trades at $22.56 (market cap $3.80B), while Regeneron Pharmaceuticals Inc trades at $671.56 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 18.5× Manchester United PLC's market cap, and Manchester United PLC pays the higher dividend (1.26%). Which is the better fit depends on your goals.
| MANU | REGN | |
|---|---|---|
Market Cap | $3.80B | $70.47B |
Sector | Media | Health |
52-Week High | $23.53 | $812.27 |
52-Week Low | $15.10 | $545.46 |
Enterprise Value | $4.72B | $64.42B |
Dividend Yield | 1.26% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $22.05, down 0.81% today, with a bullish technical signal from moving averages but mixed recent earnings performance. Revenue grew to $667M in 2025, yet net losses persist at -$33M. The company is advancing a new 100,000-seat stadium project, a key long-term growth driver, while securing Champions League qualification boosts future revenue prospects.
Outlook hinges on stadium development execution and sustained sporting success to drive profitability. Risks include high debt levels and inconsistent earnings. Analysts are cautiously optimistic with 40% buy ratings, but investors should monitor cash flow trends amid significant capital expenditures.
Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.
Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
